Fundraising FoxImara
NASDAQ: ELVNacquired by Enliven TherapeuticsCambridge, US · Founded 2016 · Delaware corporation · 10 known investors
Find your way into Imara
Sign up to see every warm intro you have to Imara
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Imara team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Enliven Therapeutics February 2023 · terms undisclosed — ~$340M (third-party estimate, not company-confirmed) · source ↗
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion. The company combines validated biological targets with drug design and clinical strategies aimed at improving patient outcomes through precision medicine approaches.
Founders & leadership
Board
Investors · 10
How we know: the S-1 prospectus · board seat on SEC Form D · press coverage · Not right? Tell us
How we know: the S-1 prospectus · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · press coverage · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$140.1M disclosed across 3 of 6 rounds · 1900–2024
▶$90MraisedApr 2024 · 20 investors · PharmaceuticalsRule 506(b)
- Helen CollinsExecutive Officer
- Andrew PhillipsDirector
- Richard HeymanDirector
- Mika DerynckDirector
- Benjamin HohlExecutive Officer
- Anish PatelExecutive Officer
- Joseph P. LyssikatosExecutive Officer, Director
- Jake BauerDirector
- Rahul BallalDirector
- Rishi GuptaDirector
- Samuel KintzExecutive Officer, Director
- Offering amount
- $90M
- Amount sold
- $90M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.1MraisedMar 2019 · 11 investors · PharmaceuticalsRule 506(b)
- David BonitaDirector
- Christoph M. AdamsExecutive Officer
- Barbara DaltonDirector
- James G. McArthurDirector
- Rahul BallalExecutive Officer, Director
- David MottDirector
- Carl GoldfischerDirector
- Mark ChinDirector
- Mette Kirstine AggerDirector
- Sara NayeemDirector
- Offering amount
- $63M
- Amount sold
- $44.1M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$6MraisedApr 2016 · 7 investors · PharmaceuticalsRule 506(b)
- Sara NayeemDirector
- Barbara DaltonDirector
- David MottDirector
- Robert HopfnerDirector
- Mette Kirstine AggerDirector
- James G. McArthurExecutive Officer, Director
- Christoph M. AdamsExecutive Officer, Director
- Offering amount
- $31M
- Amount sold
- $6M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Imara do?
- Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion. The company combines validated biological targets with drug design and clinical strategies aimed at improving patient outcomes through precision medicine approaches.
- Who are Imara's investors?
- Imara's investors include Bay City Capital, New Enterprise Associates (NEA), Pfizer Venture Investments, RA Capital, Alexandria, Arix Bioscience, JMI Equity, Lundbeckfonden Ventures and 2 more.
- How much funding has Imara raised?
- Imara has disclosed $140.1M raised across 3 of its 6 known rounds.
- Who acquired Imara?
- Imara was acquired by Enliven Therapeutics.
- Where is Imara headquartered?
- Imara is headquartered in Cambridge, US.